Cardiosphere-Derived Cell Therapy for Duchenne Muscle Degeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Duchenne muscular dystrophy, such as corticosteroids, do not address the underlying genetic abnormality and progressive muscle and heart tissue damage, leading to significant comorbidities like cardiomyopathy and respiratory failure, with no effective therapeutic options for late-stage heart failure.
Innovation Solution
Administration of cardiosphere-derived cells (CDCs) or exosomes derived from CDCs (CDC-XOs) to patients, either systemically or locally, to treat skeletal muscular dystrophy, including Duchenne and Becker muscular dystrophy, by improving muscle function and integrity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If corticosteroids are used to treat Duchenne muscular dystrophy, then muscle inflammation is reduced, but the underlying genetic abnormality and progressive tissue damage are not addressed
Solution Approach 1:
The patent uses cardiosphere-derived cells (CDCs) as intermediary therapeutic agents that can cross the sarcolemmal membrane barrier created by dystrophin deficiency. These cells deliver therapeutic effects to both skeletal and cardiac muscle tissue, addressing the root cause of progressive tissue damage while reducing inflammation, thereby overcoming the limitations of corticosteroid therapy
2Reliability
If no specific treatment is provided for Duchenne muscular dystrophy, then the genetic abnormality remains unaddressed, but current available treatments do not prevent progressive muscle and heart tissue damage
Solution Approach 1:
The patent employs cardiosphere-derived cells that are harvested, expanded, and preconditioned in vitro before administration to patients. This preliminary preparation allows the cells to be optimized for therapeutic efficacy, enabling them to prevent progressive tissue damage when administered at appropriate stages of disease progression, rather than waiting for end-stage failure
Solution Approach 2:
The cardiosphere-derived cells possess intrinsic self-renewal and self-differentiation capabilities that allow them to home to both skeletal and cardiac muscle tissues, differentiate into appropriate cell types, and provide sustained therapeutic effects without requiring external support systems or repeated administrations
3Reliability
If cell or tissue transplantation is performed for late-stage heart failure, then cardiac function may be restored, but patients with advanced heart failure are excluded from these treatments
Solution Approach 1:
The patent utilizes cardiosphere-derived cells that can be expanded to large numbers in culture and administered systemically. These cells are designed to be transient but highly effective, providing sufficient therapeutic benefit during the window of opportunity before end-stage failure, thereby expanding access to cell-based therapies for patients who would otherwise be excluded
Data Source
Figure 1A~1C
Figure 1D
Figure 1E
AI summary
Some embodiments provide a method of treating skeletal muscular myopathy, e.g., Duchenne muscular dystrophy (DMD), with cardiosphere-derived cells (CDCs), wherein a therapeutically effective amount of CDCs is delivered to a targeted dystrophic skeletal muscle. Some embodiment enable delivery of a therapeutically effective amount of CDCs via intramuscular injection directly at a skeletal muscle or systemic administration, e.g., intravenous injection, in a single dose or multiple doses, to treat a targeted dystrophic skeletal muscle. Some embodiments provide a method for improving exercise capabilities in DMD patients. Additional embodiments relate to exosome mediated transfer of noncoding RNAs ameliorates Duchenne muscular dystrophy by restoring dystrophin in heart and skeletal muscle. Delivery of noncoding RNA species found in CDC-derived exosomes mimics the ability of CDCs and CDC-derived exosomes to increase dystrophin protein levels.